Taiwan · Delayed Price · Currency is TWD PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 544.16 billion. The enterprise value is 520.94 billion.
| Market Cap | 544.16B |
| Enterprise Value | 520.94B |
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | Jul 9, 2026 |
Share Statistics
PharmaEssentia has 412.24 million shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | 412.24M |
| Shares Outstanding | 412.24M |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 8.11% |
| Owned by Institutions (%) | 10.82% |
| Float | 328.29M |
Valuation Ratios
The trailing PE ratio is 91.73 and the forward PE ratio is 48.56.
| PE Ratio | 91.73 |
| Forward PE | 48.56 |
| PS Ratio | 31.10 |
| PB Ratio | 15.79 |
| P/TBV Ratio | 15.90 |
| P/FCF Ratio | 147.51 |
| P/OCF Ratio | 91.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 83.02, with an EV/FCF ratio of 141.22.
| EV / Earnings | 87.83 |
| EV / Sales | 29.77 |
| EV / EBITDA | 83.02 |
| EV / EBIT | 88.24 |
| EV / FCF | 141.22 |
Financial Position
The company has a current ratio of 6.53, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.53 |
| Quick Ratio | 6.13 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.26 |
| Interest Coverage | 237.89 |
Financial Efficiency
Return on equity (ROE) is 18.66% and return on invested capital (ROIC) is 55.29%.
| Return on Equity (ROE) | 18.66% |
| Return on Assets (ROA) | 10.10% |
| Return on Invested Capital (ROIC) | 55.29% |
| Return on Capital Employed (ROCE) | 16.72% |
| Weighted Average Cost of Capital (WACC) | 7.29% |
| Revenue Per Employee | 133.58M |
| Profits Per Employee | 45.28M |
| Employee Count | 131 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.46 |
Taxes
| Income Tax | -73.20M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +210.10% in the last 52 weeks. The beta is 0.55, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +210.10% |
| 50-Day Moving Average | 916.84 |
| 200-Day Moving Average | 617.74 |
| Relative Strength Index (RSI) | 68.60 |
| Average Volume (20 Days) | 3,461,462 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 17.50 billion and earned 5.93 billion in profits. Earnings per share was 14.39.
| Revenue | 17.50B |
| Gross Profit | 15.56B |
| Operating Income | 5.91B |
| Pretax Income | 5.86B |
| Net Income | 5.93B |
| EBITDA | 6.06B |
| EBIT | 5.91B |
| Earnings Per Share (EPS) | 14.39 |
Balance Sheet
The company has 24.18 billion in cash and 961.16 million in debt, with a net cash position of 23.21 billion or 56.31 per share.
| Cash & Cash Equivalents | 24.18B |
| Total Debt | 961.16M |
| Net Cash | 23.21B |
| Net Cash Per Share | 56.31 |
| Equity (Book Value) | 34.45B |
| Book Value Per Share | 83.58 |
| Working Capital | 26.19B |
Cash Flow
In the last 12 months, operating cash flow was 5.95 billion and capital expenditures -2.26 billion, giving a free cash flow of 3.69 billion.
| Operating Cash Flow | 5.95B |
| Capital Expenditures | -2.26B |
| Depreciation & Amortization | 152.57M |
| Net Borrowing | -226.96M |
| Free Cash Flow | 3.69B |
| FCF Per Share | 8.95 |
Margins
Gross margin is 88.90%, with operating and profit margins of 33.77% and 33.90%.
| Gross Margin | 88.90% |
| Operating Margin | 33.77% |
| Pretax Margin | 33.48% |
| Profit Margin | 33.90% |
| EBITDA Margin | 34.65% |
| EBIT Margin | 33.77% |
| FCF Margin | 21.08% |
Dividends & Yields
This stock pays an annual dividend of 0.99, which amounts to a dividend yield of 0.08%.
| Dividend Per Share | 0.99 |
| Dividend Yield | 0.08% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 6.17% |
| Buyback Yield | -0.22% |
| Shareholder Yield | -0.14% |
| Earnings Yield | 1.09% |
| FCF Yield | 0.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for PharmaEssentia is 1,057.48, which is -17.71% lower than the current price. The consensus rating is "Buy".
| Price Target | 1,057.48 |
| Price Target Difference | -17.71% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 39.38% |
| EPS Growth Forecast (3Y) | 45.95% |
Stock Splits
The last stock split was on July 9, 2026. It was a forward split with a ratio of 1.10927783.
| Last Split Date | Jul 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.10927783 |
Scores
PharmaEssentia has an Altman Z-Score of 22.41 and a Piotroski F-Score of 7.
| Altman Z-Score | 22.41 |
| Piotroski F-Score | 7 |